Eli Lilly makes Zepbound vials cheaper for self-paying patients
Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound. | The company is adding higher-dose Zepbound options to its online pharmacy and trimming costs for its lower-dose options by $50.
Eli Lilly ( LLY 2.11%) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...
U.S. pharmaceutical giant Eli Lilly (LLY) is lowering the cost of its blockbuster weight loss medication Zepbound in an effort to reach more ...
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
Seana Smith and Brad Smith examine several stocks on the move this morning: Pharmaceutical giant Eli Lilly (LLY) is cutting ...
24/7 Wall St. on MSN23h
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk's (NYSE:NVO) was ...
Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...
4h
We recently compiled a list of the 20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years. In this article, we ...
Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback